Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.43 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069757 | 0.86 | RET (0.43) | P2RX7RETSLC6A9CCR3USP30 | |
| SCHEMBL20147559 | 0.84 | RET (0.43) | P2RX7RETCCR3ACKR3USP30 | |
| SCHEMBL20148055 | 0.83 | RET (0.41) | P2RX7RETSLC6A9CCR3USP30 | |
| SCHEMBL20158497 | 0.83 | CCR3 (0.46) | P2RX7RETSLC6A9CCR3DPP4 | |
| SCHEMBL20147543 | 0.83 | RET (0.50) | P2RX7RETCCR3ACKR3 | |
| SCHEMBL20147569 | 0.83 | CCR3 (0.43) | P2RX7RETCCR3ACKR3USP30 | |
| SCHEMBL20147576 | 0.80 | MCHR1 (0.40) | P2RX7RETCCR3 | |
| SCHEMBL20147539 | 0.80 | RET (0.46) | RETCCR3ACKR3 | |
| SCHEMBL20147572 | 0.78 | GAA (0.45) | CCR3DPP4 | |
| SCHEMBL20147567 | 0.77 | CCR3 (0.42) | RETSLC6A9CCR3ACKR3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | P2RX7 1456/4885RET 1/4885SLC6A9 3553/4885 |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | P2RX7 1456/4885RET 1/4885SLC6A9 3553/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | P2RX7 1456/4885RET 1/4885SLC6A9 3553/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | P2RX7 1456/4885RET 1/4885SLC6A9 3553/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | P2RX7 1456/4885RET 1/4885SLC6A9 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.